Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

Eduard Jonas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0123-256X; OpenAlex author ID A5069645134. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
12
Papers, trials and grants by year

2021: 6 papers · 2022: none · 2023: 1 paper · 2024: 3 papers · 2025: 2 papers

Papers 12

  1. Identification and validation of a novel autoantibody biomarker panel for differential diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2025.1494446↗
  2. Preoperative risk factors for 90-day postoperative mortality in patients with pancreatic ductal adenocarcinoma: a cohort-based study. Co-author DOI 10.36303/sajs.02398↗
  3. The role of national population-based registries in pancreatic cancer surgery research. Co-author DOI 10.1097/js9.0000000000001405↗
  4. Humoral immunoprofiling identifies novel biomarkers and an immune suppressive autoantibody phenotype at the site of disease in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2024.1330419↗
  5. Audit of an in-patient palliative care quality improvement process for patients with pancreatic ductal adenocarcinoma in a South African teaching hospital. Last author PMID 38838124↗
  6. Early detection of pancreatic adenocarcinoma. Co-author DOI 10.36303/sajs.4145↗
  7. Neoadjuvant chemotherapy for non-metastatic pancreatic cancer. Co-author DOI 10.1002/jhbp.935↗
  8. Letter to the Editor: Comment on: Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy. Co-author DOI 10.1007/s12029-021-00656-4↗
  9. Letter comments re: Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A NCDB analysis. Co-author DOI 10.1016/j.ejca.2021.09.001↗
  10. Survival equivalence in patients treated for borderline resectable and unresectable locally advanced pancreatic ductal adenocarcinoma: a systematic review and … Last author DOI 10.1016/j.hpb.2020.09.022↗
  11. Comment on "Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer". Last author DOI 10.1097/sla.0000000000004877↗
  12. Translation and linguistic validation of the EORTC QLQ-PAN26 questionnaire for assessment of health-related quality of life in patients with pancreatic cancer … Last author DOI 10.17159/2078-5151/2021/v59n4a3487↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc M. Bernon · 6 shared papers, 2021–2025 · strength 1.32
  2. Jake E.J. Krige · 6 shared papers, 2021 · strength 1.14
  3. Christo Kloppers · 4 shared papers, 2021–2025 · strength 1.11
  4. Urda K. Kotze · 5 shared papers, 2021–2025 · strength 1.07
  5. Jessica D. Lindemann · 4 shared papers, 2021 · strength 0.76
  6. Pamela Winnie M. Maimela · 2 shared papers, 2024–2025 · strength 0.47
  7. Jonathan Michael Blackburn · 2 shared papers, 2024–2025 · strength 0.47
  8. Martin Brand · 1 shared paper, 2023 · strength 0.39
  9. Clara-Marie Clasen · 1 shared paper, 2025 · strength 0.28
  10. Haytham Bayadsi · 1 shared paper, 2025 · strength 0.28
  11. Metoboroghene Oluwaseyi Mowoe · 1 shared paper, 2025 · strength 0.21
  12. K.J. Gqada · 1 shared paper, 2021 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.